Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Comparing the Use of Renuvion to a Competing Technology Following Liposuction or Body Contouring Procedures
Apyx Medical (NASDAQ:APYX) announced the publication of a peer-reviewed study in Plastic and Reconstructive Surgery—Global Open comparing their Renuvion Helium Plasma Technology to InMode's Bipolar RF System following liposuction or body contouring procedures. The study, involving over 450 patients, found that Renuvion exhibited statistically significant fewer adverse events (p-value <0.0001) compared to Bipolar RF.
Key findings include:
- 45 adverse events in 34 Renuvion patients vs. 93 in 62 Bipolar RF patients
- 28 procedure-related events with Renuvion vs. 69 with Bipolar RF
- Significantly fewer burns, hematomas, hypertrophic scars, and seromas with Renuvion
Researchers concluded that Renuvion may offer a safer alternative with shorter procedural times and higher patient satisfaction rates.
Apyx Medical (NASDAQ:APYX) ha annunciato la pubblicazione di uno studio peer-reviewed su Plastic and Reconstructive Surgery—Global Open che confronta la loro Renuvion Helium Plasma Technology con il sistema Bipolare RF di InMode a seguito di procedure di liposuzione o di rimodellamento corporeo. Lo studio, che ha coinvolto oltre 450 pazienti, ha rilevato che Renuvion ha mostrato un numero significativamente inferiore di eventi avversi (p-value <0.0001) rispetto al sistema Bipolare RF.
I risultati chiave includono:
- 45 eventi avversi in 34 pazienti trattati con Renuvion contro 93 in 62 pazienti trattati con Bipolar RF
- 28 eventi correlati alla procedura con Renuvion contro 69 con Bipolar RF
- Numero significativamente inferiore di ustioni, ematomi, cicatrici ipertrofiche e sieromi con Renuvion
I ricercatori hanno concluso che Renuvion può offrire un alternativa più sicura con tempi di procedura più brevi e tassi di soddisfazione del paziente più elevati.
Apyx Medical (NASDAQ:APYX) anunció la publicación de un estudio revisado por pares en Plastic and Reconstructive Surgery—Global Open que compara su Renuvion Helium Plasma Technology con el sistema Bipolar RF de InMode después de procedimientos de liposucción o contorno corporal. El estudio, que involucró a más de 450 pacientes, encontró que Renuvion mostró significativamente menos eventos adversos (p-value <0.0001) en comparación con Bipolar RF.
Los hallazgos clave incluyen:
- 45 eventos adversos en 34 pacientes de Renuvion frente a 93 en 62 pacientes de Bipolar RF
- 28 eventos relacionados con el procedimiento con Renuvion frente a 69 con Bipolar RF
- Significativamente menos quemaduras, hematomas, cicatrices hipertróficas y seromas con Renuvion
Los investigadores concluyeron que Renuvion puede ofrecer una alternativa más segura con tiempos de procedimiento más cortos y tasas de satisfacción del paciente más altas.
Apyx Medical (NASDAQ:APYX)는 지방 흡입술 또는 신체 윤곽 시술 후 Renuvion Helium Plasma Technology와 InMode의 Bipolar RF System을 비교한 동료 검토 연구의 발표를 알렸습니다. 450명 이상의 환자가 참여한 이 연구에서 Renuvion은 Bipolar RF에 비해 통계적으로 유의미한 적은 부작용을 나타냈습니다 (p-값 <0.0001).
주요 발견은 다음과 같습니다:
- Renuvion 환자 34명에서 45건의 부작용, Bipolar RF 환자 62명에서 93건
- Renuvion에서 28건의 시술 관련 사건, Bipolar RF에서 69건
- Renuvion으로 적은 화상, 혈종, 비대성 흉터 및 액체 고임
연구자들은 Renuvion이 더 안전한 대안을 제공할 수 있으며 시술 시간이 짧고 환자 만족도가 높을 수 있다고 결론지었습니다.
Apyx Medical (NASDAQ:APYX) a annoncé la publication d'une étude revue par des pairs dans Plastic and Reconstructive Surgery—Global Open comparant leur Renuvion Helium Plasma Technology au système Bipolaire RF d'InMode suite à des procédures de liposuccion ou de remodelage corporel. L'étude, impliquant plus de 450 patients, a révélé que Renuvion présentait un nombre d'événements indésirables statistiquement significativement inférieur (p-value <0.0001) par rapport au Bipolaire RF.
Les principaux résultats incluent :
- 45 événements indésirables chez 34 patients sous Renuvion contre 93 chez 62 patients sous Bipolaire RF
- 28 événements liés à la procédure avec Renuvion contre 69 avec Bipolaire RF
- Un nombre significativement inférieur de brûlures, d'hématomes, de cicatrices hypertrophiques et de séromes avec Renuvion
Les chercheurs ont conclu que Renuvion pourrait offrir une alternative plus sûre avec des temps de procédure plus courts et des taux de satisfaction des patients plus élevés.
Apyx Medical (NASDAQ:APYX) gab die Veröffentlichung einer von Experten begutachteten Studie in Plastic and Reconstructive Surgery—Global Open bekannt, die ihre Renuvion Helium Plasma Technology mit dem Bipolar RF-System von InMode nach Fettabsaugungs- oder Körperkonturierungsverfahren vergleicht. Die Studie, an der über 450 Patienten beteiligt waren, ergab, dass Renuvion statistisch signifikant weniger unerwünschte Ereignisse aufwies (p-Wert <0.0001) im Vergleich zu Bipolar RF.
Wichtige Ergebnisse sind:
- 45 unerwünschte Ereignisse bei 34 Renuvion-Patienten im Vergleich zu 93 bei 62 Bipolar RF-Patienten
- 28 verfahrenbezogene Ereignisse mit Renuvion im Vergleich zu 69 mit Bipolar RF
- Deutlich weniger Verbrennungen, Hämatome, hypertrophe Narben und Serome bei Renuvion
Die Forscher kamen zu dem Schluss, dass Renuvion eine sichere Alternative mit kürzeren Verfahrenszeiten und höheren Patientenzufriedenheitsraten bieten kann.
- Renuvion showed statistically significant fewer adverse events compared to competing technology
- Study published in a peer-reviewed, open access journal, adding credibility to findings
- Renuvion demonstrated shorter procedural times and higher patient satisfaction rates
- Results support enhanced safety outcomes of Renuvion in treating loose skin after liposuction
- None.
This peer-reviewed study comparing Renuvion to Bipolar RF technology is highly significant for Apyx Medical. The research demonstrates a statistically significant reduction in adverse events (
Key findings include:
- 45 adverse events in 34 Renuvion patients vs. 93 in 62 Bipolar RF patients
- Notably fewer burns, hematomas, hypertrophic scars and seromas with Renuvion
- Shorter procedural times and higher patient satisfaction rates for Renuvion
These results could lead to increased adoption of Renuvion technology, potentially boosting Apyx's market share and revenue. However, investors should note that this is a single-center study and broader, multi-center trials would further solidify these findings.
This clinical publication could have a substantial positive impact on Apyx Medical's financial outlook. The demonstrated superior safety profile of Renuvion over a competing technology may lead to:
- Increased market adoption and sales growth
- Potential for premium pricing
- Reduced liability risks and associated costs
- Enhanced brand reputation in the cosmetic surgery market
However, investors should consider that the full financial impact may take time to materialize as medical professionals and institutions adjust their practices. Additionally, while the study is promising, it's important to monitor how this translates into actual sales figures and market share gains in upcoming quarterly reports. The company's ability to leverage these results in marketing and sales strategies will be key to realizing the potential financial benefits.
This publication could significantly shift market dynamics in the cosmetic surgery sector. With Renuvion demonstrating superior safety outcomes, we might see:
- A potential market share shift from InMode's Bipolar RF to Apyx's Renuvion
- Increased interest from cosmetic surgeons and clinics in adopting Renuvion
- Possible changes in insurance company preferences or coverage decisions
- Enhanced positioning of Apyx Medical as a leader in innovative, safe cosmetic technologies
The global body contouring market, valued at
Demonstrates a statistically significant reduction in adverse events associated with the use of Renuvion following liposuction or body contouring, compared to the competing technology
In this retrospective, single-center, contiguous series study, researchers Michael Kluska, DO et al. collected demographic, procedure and safety data from more than 450 patients who underwent treatment with either Renuvion (n=229) or Bipolar RF (n=236) following liposuction or body contouring procedures. The demographic characteristics of both groups exhibited similarity in terms of age, sex, BMI and tobacco usage.
The researchers analyzed adverse events documented during and post-procedure by body area for both groups. Based on this analysis, they found that the group treated with Renuvion exhibited statistically significant fewer adverse events (p-value <0.0001), compared to the group treated with Bipolar RF. Specifically, 45 adverse events were documented in 34 of the patients treated with Renuvion, compared to 93 adverse events documented in 62 of the patients treated with Bipolar RF. 28 adverse events documented in the Renuvion group were determined to be procedure-related, compared to 69 events in the Bipolar RF group. The researchers found the significantly fewer occurrences of burns, hematoma, hypertrophic scar, and seroma in the Renuvion group to be particularly noteworthy.
Based on these findings, the researchers concluded that Renuvion may offer a safer alternative to Bipolar RF following liposuction or body contouring procedures. They observed that the study’s findings underscore the importance of carefully selecting the appropriate energy-based technology for managing skin laxity following liposuction or body contouring procedures, and added that Renuvion emerges as a promising option over Bipolar RF due to its superior safety profile, shorter procedural times and higher patient satisfaction rates compared to Bipolar RF.
“We are pleased to see the results of this important clinical study published in a peer-reviewed, open access journal, following its presentation at the American Academy of Cosmetic Surgery Scientific Meeting earlier this year,” said Charlie Goodwin, President and Chief Executive Officer. “Its findings support the enhanced safety outcomes that can be achieved when using Renuvion to treat loose skin following liposuction or body contouring procedures, as compared to a commonly-used competing technology. Apyx Medical remains committed to bringing innovative, evidence-based medicine to surgeons and patients in the global cosmetic surgery market, and we believe the study represents an important addition to the extensive body of clinical evidence supporting the safety and efficacy of our Renuvion technology.”
A digital version of the clinical publication is available via the following link: Plastic and Reconstructive Surgery – Global Open (lww.com)
About Apyx Medical Corporation:
Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website www.ApyxMedical.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240808954609/en/
Investor Relations:
ICR Westwicke on behalf of Apyx Medical Corporation
Mike Piccinino, CFA
investor.relations@apyxmedical.com
Source: Apyx Medical Corporation
FAQ
What were the key findings of the Renuvion vs Bipolar RF study for APYX stock?
How many patients were involved in the Apyx Medical's Renuvion study?
What advantages does Renuvion offer over Bipolar RF according to the APYX study?
Where was the Apyx Medical's Renuvion study published?
